Current and future directions in theranostics for neuroendocrine prostate cancer

This publication has 76 references indexed in Scilit:

• Oncofetal protein glypican‐3 is a biomarker and critical regulator of function for neuroendocrine cells in prostate cancer
  The Journal of Pathology, 2023
• Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies
  European Journal of Nuclear Medicine and Molecular Imaging, 2023
• Role of tumor microenvironment in cancer progression and therapeutic strategy
  Cancer Medicine, 2023
• SSTR-based theranostics in neuroendocrine prostate cancer (NEPC)
  Clinical and Translational Imaging, 2022
• Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
  Journal of Cancer Research and Clinical Oncology, 2022
• High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics
  European Journal of Nuclear Medicine and Molecular Imaging, 2021
• Clinical and Biological Features of Neuroendocrine Prostate Cancer
  Current Oncology Reports, 2021
• SRRM4 gene expression correlates with neuroendocrine prostate cancer
  The Prostate, 2018
• Somatostatin receptor subtype 1 as a potential diagnostic marker and therapeutic target in prostate cancer
  The Prostate, 2017
• Early over‐expression of GRP receptors in prostatic carcinogenesis
  The Prostate, 2013